Alpha-lipoic acid (ALA) is a mitochondria-native antioxidant that crosses the blood-brain barrier, regenerates glutathione and vitamin C, and is one of the few compounds with robust clinical evidence for peripheral neuropathy. R-ALA (the natural isomer) is roughly twice as bioavailable as the racemic mixture. At therapeutic doses (600–1,200 mg/day), ALA is a meaningful adjunct in heavy metal chelation protocols, Lyme-related nerve damage, and metabolic syndrome. It is not a standalone chelator, but its glutathione-sparing and mitochondrial-protective effects make it a practical component of integrative detox strategies.

Every cell in your body has tiny power plants called mitochondria. Alpha-lipoic acid is a natural molecule those power plants make to protect themselves from rust (oxidative stress). As a supplement, it acts like a master antioxidant that helps regenerate other antioxidants, protects nerves, and helps the body handle unwanted metals.

At a Glance

Feature	Detail
Full name	Alpha-lipoic acid (ALA), also thioctic acid
Best form	R-ALA (natural isomer); racemic (R+S) is more common and cheaper
Standard dose	300–600 mg racemic; 150–300 mg R-ALA (equivalently)
Therapeutic dose (neuropathy)	600–1,200 mg/day racemic or 300–600 mg R-ALA
Key mechanisms	Mitochondrial cofactor, glutathione regeneration, NF-κB inhibition, metal chelation
Half-life	~30 minutes (racemic); R-ALA slightly longer
Take with food?	Racemic: empty stomach for peak absorption; R-ALA: better tolerated with small meal
Crosses blood-brain barrier?	Yes — one of few antioxidants that does
Drug interactions	May potentiate metformin/insulin; space from thyroid medications

Alpha-lipoic acid sits at an unusual intersection in integrative medicine: it is simultaneously a mitochondrial cofactor made endogenously, a clinically validated agent for diabetic neuropathy, a glutathione precursor, and a weak but synergistic chelation adjunct. Unlike many supplements with theoretical mechanisms and thin human data, ALA has a genuine evidence base — including IV trials for neuropathy in Germany that span three decades. Understanding where that evidence is strong and where it is extrapolated is essential before building it into a protocol.

What Alpha-Lipoic Acid Actually Does in the Cell

ALA is a cofactor for two critical mitochondrial enzyme complexes — pyruvate dehydrogenase and α-ketoglutarate dehydrogenase — meaning it sits squarely inside the machinery that converts glucose into cellular energy. This endogenous role is important context: ALA is not a foreign molecule; it is something the body already synthesizes, and supplementation raises levels beyond baseline rather than introducing a novel compound.

Its antioxidant properties operate through several parallel mechanisms:

Direct radical scavenging. Both the oxidized (ALA) and reduced (dihydrolipoic acid, DHLA) forms neutralize reactive oxygen species. DHLA — the form produced inside cells after ALA is reduced — is a particularly potent reductant.

Network antioxidant recycling. DHLA regenerates oxidized glutathione, vitamin C, and vitamin E back to their active forms. This “antioxidant recycling” effect means ALA amplifies the capacity of the entire antioxidant network rather than simply acting as a single scavenger. In patients with depleted glutathione — a common finding in chronic Lyme disease, heavy metal burden, and post-COVID states — this recycling effect can be clinically significant.

NF-κB and inflammatory pathway modulation. At higher doses, ALA suppresses nuclear factor kappa B, a master regulator of pro-inflammatory cytokine transcription. This partly explains its observed benefits in inflammatory neuropathy and autoimmune conditions beyond simple oxidative stress reduction.

Mild metal chelation. ALA and DHLA bind divalent cations including mercury, cadmium, arsenic, and copper via sulfhydryl groups. This chelation is weaker and less selective than agents like DMSA or DMPS, but may be relevant in contexts where redistribution rather than aggressive extraction is the goal.

R-ALA vs. Racemic ALA: Does the Isomer Matter?

ALA is a chiral molecule with two mirror-image forms. The R-isomer is the biologically active form produced in nature and found in mitochondria. Commercial synthesis yields a 50/50 mixture (racemic) of R-ALA and S-ALA.

Why it matters clinically:

R-ALA has approximately 40–50% higher bioavailability than the S-form
R-ALA is more potent at enzyme cofactor sites
S-ALA may competitively inhibit some of R-ALA’s effects at high doses in animal models (though human clinical significance is debated)
R-ALA is substantially more expensive and less thermostable

Practical implication: For general supplementation (metabolic support, longevity stack), racemic ALA at 300–600 mg is cost-effective and adequately studied. For therapeutic targets — neuropathy, significant oxidative load, or chelation adjunct protocols — R-ALA at 150–300 mg provides equivalent or superior effect at lower absolute dose. Sodium-R-ALA (a stabilized salt form) improves thermal stability and is preferred in clinical formulations.

In my practice, we typically use racemic ALA in standard protocols and switch to sodium-R-ALA when we are targeting neurological endpoints or working alongside a DMSA/DMPS chelation cycle.

Clinical Evidence for Neuropathy

The strongest human evidence for ALA is in peripheral neuropathy, particularly diabetic peripheral neuropathy (DPN). This is not marginal data — it is multi-center randomized controlled trial data with patient-reported outcomes.

The ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) study series, published across the 1990s and 2000s, established that IV ALA at 600 mg/day for 3 weeks significantly reduced neuropathic symptoms (pain, burning, paresthesia, numbness) compared to placebo. The SYDNEY-2 trial confirmed oral benefit: 600 mg/day racemic ALA for 5 weeks produced significant symptom reduction versus placebo.

A 2012 meta-analysis in Diabetes/Metabolism Research and Reviews pooling four placebo-controlled RCTs (n=1,258) found that 600 mg/day IV ALA over 3 weeks reduced the Total Symptom Score by ~50% compared to ~30% for placebo — a clinically meaningful difference.

Mechanism in neuropathy: Peripheral nerves are exceptionally vulnerable to oxidative stress because of their high lipid content and long axonal distances. ALA reduces oxidative modification of nerve lipids, improves endoneurial blood flow, and may support remyelination through Schwann cell protection.

Relevance beyond diabetic neuropathy:

Lyme neuroborreliosis: The mechanism of nerve damage in neuroborreliosis — oxidative stress, microglial activation, mitochondrial dysfunction — mirrors that of diabetic neuropathy, making ALA a rational adjunct. Direct RCT evidence in Lyme-specific neuropathy is absent, but mechanistic and case series data support its use in our protocols.
Chemotherapy-induced peripheral neuropathy (CIPN): Small trials suggest ALA may attenuate CIPN severity, though data remain preliminary.
Autonomic neuropathy: Some evidence for cardiac autonomic dysfunction improvement in diabetic cohorts; clinically relevant for patients with dysautonomia (common in chronic Lyme and post-COVID).

ALA in Heavy Metal Chelation Protocols

This is where clinical application extends beyond the direct evidence base, so it requires careful framing.

What ALA does in chelation: As a dithiol compound, ALA and its reduced form DHLA bind mercury, arsenic, cadmium, and lead. Unlike DMSA (meso-2,3-dimercaptosuccinic acid) or DMPS, which are true chelating agents used in established protocols, ALA’s chelation affinity is lower and less selective.

The key concern with ALA as a chelator: ALA can mobilize mercury from tissue stores and, if given infrequently or at doses that don’t sustain adequate blood levels throughout the half-life, may redistribute mercury to the brain rather than facilitating urinary excretion. This concern, raised prominently by Andrew Cutler’s chelation protocol framework, argues that ALA should be dosed every 3–4 hours during chelation rounds (matching its short half-life) to maintain continuous chelation without redistribution windows.

How I use ALA in heavy metal protocols:

Not as a primary chelator (we use DMSA or DMPS for that, under careful monitoring)
As a preparatory and supportive agent — given daily for 4–8 weeks prior to chelation cycles to reduce oxidative burden and support glutathione status
During chelation cycles, specifically to support mitochondrial protection and nerve function
Post-chelation, to assist hepatic antioxidant recovery

Patients undergoing our heavy metal chelation protocol typically receive ALA alongside NAC, glutathione support, and B vitamins — addressing the multi-system oxidative burden rather than relying on any single agent.

Metabolic and Longevity Applications

Beyond neuropathy and detox, ALA has well-documented metabolic effects that make it a practical component of longevity and metabolic health protocols:

Insulin sensitivity. ALA activates GLUT4 translocation and insulin signaling (PI3K/Akt pathway), improving glucose uptake independent of insulin. Multiple RCTs confirm improvements in insulin sensitivity markers in prediabetic and type 2 diabetic cohorts. At 600–1,200 mg/day, reductions in fasting glucose and HbA1c are modest but consistent.

Mitochondrial biogenesis support. ALA activates AMPK (via mild energy stress mimicry) and upregulates PGC-1α, pathways that drive mitochondrial biogenesis. This overlaps mechanistically with berberine and exercise — synergy that is frequently exploited in longevity stacks.

Telomere and DNA protection. DHLA reduces 8-OHdG (a marker of oxidative DNA damage) in multiple cell types. Whether this translates to longevity benefit in humans remains unproven, but the mechanism is plausible.

Combination with CoQ10: Mitochondrial antioxidant pairing of ALA and CoQ10 is well-studied. The two agents protect different mitochondrial compartments (CoQ10 the inner membrane electron transport chain; ALA the matrix enzyme complexes), and animal data consistently show additive benefit on mitochondrial function and oxidative parameters. We frequently combine them in longevity protocols.

Dosing, Timing, and Practical Considerations

Standard supplementation (metabolic/longevity):

Racemic ALA: 300–600 mg/day in divided doses
R-ALA: 150–300 mg/day
Take on empty stomach for peak absorption (racemic); sodium-R-ALA can be taken with food

Therapeutic (neuropathy, chelation adjunct):

Racemic ALA: 600–1,200 mg/day in 2–3 divided doses
R-ALA: 300–600 mg/day in divided doses
IV ALA (600 mg in 250 mL saline over 30 min) for acute neuropathy — only in clinical settings

Key interactions and cautions:

Insulin/hypoglycemic agents: ALA can lower blood glucose; monitor closely in medicated diabetic patients
Thyroid medications (levothyroxine): Space ALA by at least 2 hours as it may impair absorption
Biotin competition: High-dose ALA may compete with biotin for cellular transport; supplement biotin separately if using long-term high doses
Thiamine-deficient states: ALA theoretically increases thiamine requirement; ensure B-vitamin adequacy
Pregnancy: Insufficient safety data; avoid at therapeutic doses

Safety profile: ALA has a strong safety record at 600–1,200 mg/day in published trials spanning years. The most common side effects are gastrointestinal (nausea, stomach discomfort) at higher doses — usually resolved by taking with food or reducing dose. Skin rash is reported rarely. No significant hepatotoxicity in the literature at standard doses.

References

Ziegler D, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425-1433. PubMed
Ziegler D, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-2370. PubMed
Mijnhout GS, et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. PubMed
Shay KP, et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149-1160. PubMed
Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19(2):227-250. PubMed
Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69. PubMed
Sola S, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Circulation. 2005;111(3):343-348. PubMed

Alpha-Lipoic Acid: Neuropathy, Heavy Metal Detox, and Mitochondrial Repair